Cargando…

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

OBJECTIVE: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. METHODS: HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatell, José M., Assoumou, Lambert, Moyle, Graeme, Waters, Laura, Johnson, Margaret, Domingo, Pere, Fox, Julie, Martinez, Esteban, Stellbrink, Hans–Jürgen, Guaraldi, Giovanni, Masia, Mar, Gompels, Mark, De Wit, Stephane, Florence, Eric, Esser, Stefan, Raffi, François, Pozniak, Anton L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690310/ https://www.ncbi.nlm.nih.gov/pubmed/29112070 http://dx.doi.org/10.1097/QAD.0000000000001675

Ejemplares similares

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial
por: Ammassari, Adriana, et al.
Publicado: (2018)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study
por: Weidlich, Simon, et al.
Publicado: (2020)

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
por: Verna, John, et al.
Publicado: (2018)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
por: Jabłonowska, Elżbieta, et al.
Publicado: (2019)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: M. Llibre, Josep, et al.
Publicado: (2016)

Ritonavir and COVID-19: pragmatic guidance is important
por: Waters, Laura, et al.
Publicado: (2022)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: Llibre, Josep M., et al.
Publicado: (2016)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells
por: Auclair, Martine, et al.
Publicado: (2020)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
por: Rodrigues, Janine, et al.
Publicado: (2023)

Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
por: Tan, M, et al.
Publicado: (2019)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

1614 High Rates of Preterm Birth and Small for Gestational Age in a Cohort of HIV Infected Women in Canada: Role of Ritonavir Boosted Regimens?
por: Kakkar, Fatima, et al.
Publicado: (2014)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r)-Containing Regimens in Treatment-Experienced Patients with HIV
por: Svedhem-Johansson, Veronica, et al.
Publicado: (2013)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8992ihpqp6j2oiio8bfo0uumba